國家衛生研究院 NHRI:Item 3990099045/2824
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 909269      在线人数 : 799
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/2824


    题名: Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
    作者: Ch'ang, HJ;Wang, CC;Cheng, AL;Hsu, C;Lu, YS;Chang, MC;Lin, JT;Wang, HP;Shiah, HS;Liu, TW;Chang, JY;Whang-Peng, J;Chen, LT
    贡献者: National Institute of Cancer Research
    摘要: Objectives To evaluate the feasibility and maximal tolerated dose (MTD) of oxaliplatin of a triplet regimen consisting of gemcitabine, oxaliplatin and infusional fluorouracil (5-FU)/leucovorin (LV) (GOFL) for advanced pancreatic cancer. Patients and Methods Patients with histologically proven metastatic or unresectable, locally advanced pancreatic adenocarcinoma were eligible to take part in the study. The treatment consisted of fixed-rate infusion (10 mg/m(2)/minute) of 800 mg/m(2) gemcitabine followed by 2-h infusion of oxaliplatin and then 48-h infusion of 5-FU/LV day 1 and day 15 every 4 weeks. The oxaliplatin would be evaluated at three dose levels, 65, 75 and 85 mg/m(2). Results A total of 15 patients were enrolled at three dose levels. Dose-limiting toxicity of neutropenic fever and grade 4 thrombocytopenia occurred in one of each six patients at oxaliplatin dose level of 65 mg/m(2) and 85 mg/m(2), respectively. The MTD of oxaliplatin for this combination was 85 mg/m(2). After a median four cycles of treatment, grade 3/4 neutropenia occurred in 46.7% of patients and thrombocytopenia in 13.3%. Non-hematological toxicities were generally of grade 1/2. Objective tumor response was observed in five patients (33.3%, 95% confidence interval, 6.3-60.4%). Conclusion Biweekly GOFL is a feasible regimen for advanced pancreatic cancer. For further phase II studies, the recommended dose of oxaliplatin is 85 mg/m(2).(c) 2005 Blackwell Publishing Asia Pty Ltd.
    关键词: Gastroenterology & Hepatology
    日期: 2006-05
    關聯: Journal of Gastroenterology and Hepatology. 2006 May;21(5):874-879.
    Link to: http://dx.doi.org/10.1111/j.1440-1746.2005.04022.x
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0815-9319&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000237464600016
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33646900006
    显示于类别:[陳立宗] 期刊論文
    [劉滄梧] 期刊論文
    [夏和雄(1996-2012)] 期刊論文
    [常慧如] 期刊論文
    [張俊彥] 期刊論文
    [彭汪嘉康(1996-2007)] 期刊論文
    [王全正(1996-2003)] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    000237464600016.pdf76KbAdobe PDF1478检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈